Conference Coverage
Conference Coverage
VIDEO: Goserelin helps dodge ovarian failure in HR-negative breast cancer
Conference Coverage
Topical lidocaine reduces menopausal dyspareunia
Key clinical point: Consider lidocaine as an option for women with severe menopausal dyspareunia for whom estrogen therapy is not recommended....
Conference Coverage
New insights into aromatase inhibitor therapy nonpersistence
Major finding: Breast cancer patients with at least three of five self-reported symptoms prior to going on adjuvant aromatase inhibitor therapy...
Conference Coverage
Findings set stage for immunomodulatory approaches in breast cancer
Major finding: For every 10% increment in stromal tumor-infiltrating lymphocytes present at the time of diagnosis of HER2-positive breast cancer,...
Conference Coverage
Add-on agents boost neoadjuvant chemo response in triple-negative disease
Major finding: Carboplatin improved the odds of pCR by 71%-76% with some additional toxicity; bevacizumab improved the odds of pCR by 58% with...
Conference Coverage
Veliparib-carboplatin combo is first 'graduate' of I-SPY2 trial
Major finding: Among patients with triple-negative disease, there was a 90% predictive probability that veliparib-carboplatin added to...
Conference Coverage
Exercise dampens aromatase inhibitor–related joint pain
Major finding: Breast cancer patients experienced a 30% reduction in aromatase inhibitor–related joint pain, with pain scores going from moderate...
Conference Coverage
Dasatinib gives letrozole a boost in HR-positive advanced breast cancer
Major finding: Adding dasatinib to letrozole did not improve the clinical benefit rate, but it more than doubled median progression-free survival...
Conference Coverage
Radiotherapy can be omitted for many older breast cancer patients
Major finding: The 5-year ipsilateral breast cancer recurrence rate in a selected population of older women undergoing breast-conserving surgery...
Conference Coverage
Breast cancer hormone therapy may affect cognitive function
Major finding: The odds of any decline in cognitive function were significantly higher in patients on hormone therapy (OR, 7.7), compared with...